The clinical impact of multiresistant gram-positive microoraganisms in long-term care facilities

Journal of the American Medical Directors Association

Volumn 4, Issue 3 SUPPL., 2003, Pages

  Raz, Raul ^a,b  

^a HAEMEK MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; AVOPARCIN; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GATIFLOXACIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SEROTONIN AGONIST; TEICOPLANIN; TELITHROMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTHRALGIA; BACTERIAL INFECTION; BONE MARROW TOXICITY; DIARRHEA; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TARGETING; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HEADACHE; HEALTH CARE FACILITY; HUMAN; HYPERTENSIVE CRISIS; LONG TERM CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MYALGIA; NAUSEA; NONHUMAN; PHLEBITIS; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA;

EID: 0038147402     PISSN: 15258610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70339-4     Document Type: Review

References (53)

1. Nicolle LE, Garibaldi R, Strausbaugh LJ. Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev 1996;9:1-17.
2. Terpenning MS, Bradley SF, Wan JY, et al. Colonization and infection with antibiotic-resistant bacteria in a long-term care facility. J Am Geriatr Soc 1980;42:1062-1069.
3. Strausbaugh LJ, Crossley KB, Nurse BA, Thrupp LD. Antimicrobial resistance in long term care facilities. Infect Control Hosp Epidemiol 1996;17:129-140.
4. Crossley K. Vancomycin-resistant enterococci in long-term care facilities. Infect Control Hosp Epidemiol 1998;19:521-525.
5. Yoshikawa TT. Antimicrobial resistance and aging: Beginning of the end of the antibiotic era? J Am Geriatr Soc 2002;50(7 Suppl):S226-S229.
6. Strausbaugh LJ, Jacobson C, Sewell DL, et al. Methicillin-resistant staphylococcus aureus in extended-care facilities: experiences in a Veterans' Affairs nursing home and a review of the literature. Infect Control Hosp Epidemiol 1991;12:36-45.
7. Shlaes DM, Currie-McCumber CA, Lehman MH. Introduction of a plasmid encoding the OHIO-1 β-lactamase to an intermediate care ward by patient transfer. Infect Control Hosp Epidemiol 1988;9:317-319.
8. Muder RR, Brennen C, Wagener MW, et al. Methicillin-resistant staphylococcus colonization and infection in a long-term care facility. Ann Intern Med 1991;114:107-112.
9. Nicolle LE, Bentley DW, Garibaldi RA, et al. Antimicrobial use in long-term-care facilities. Infect Control Hosp Epidemiol 1996;17:119-128.
10. Gaynes RP, Weinstein RA, Chamberlin W, Kabins SA. Antibiotic-resistant flora in nursing home patients admitted to the hospital. Arch Intern Med 1985;145:1804-1807.
11. Garibaldi RA, Brodine S, Matsumiya S. Infections among patients in nursing homes. Policies, prevalence and problems. N Engl J Med 1981; 305:731-735.
12. John JE, Ribner BS. Antibiotic resistance in long-term care facilities. Infect Control Hosp Epidemiol 1991;12:245-250.
13. Wayne SJ, Rhyne RL, Stratton M. Longitudinal prescribing patterns in a nursing home population. J Am Geriatr Soc 1992;40:53-56.
14. Crossley K, Henry K, Irvine P, Willenbring K. Antibiotic use in nursing homes: prevalence, cost and utilization review. Bull N Y Acad Med 1987;63:510-518.
15. Warren JW, Palumbo FB, Fitterman L, Speedie SM. Incidence and characteristics of antibiotic use in aged nursing home patients. J Am Geriatr Soc 1991;39:963-972.
16. Yakabowich MR, Keeley G, Montgomery PR. Impact of a formulary on personal care homes in Manitoba. Can Med Assoc J 1994;150:1601-1607.
17. Warren JW. Catheter-associated urinary tract infections. Infect Dis Clin North Am 1997;11:609-622.
18. Nicolle LE. Asymptomatic bacteriuria in the elderly. Infect Dis Clin North Am 1997;11:647-662.
19. Yoshikawa TT. MRSA, PRP and DRGNB in LTCF: Lessons to be learned from this alphabet. J Am Geriatr Soc 1998;46:241-243.
20. Trick WE, Weinstein RA, DeMarais PL, et al. Colonization of skilled care facility residents with antimicrobial-resistant pathogens. J Am Geriatr Soc 2001;49:1-7
21. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-442.
22. Barber M. Methicillin-resistant staphylococci. J Clin Pathol 1961;14: 385-393.
23. Jacoby GA, Archer GL. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 1991;324:601-612.
24. Anonymous. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. Morbid Mortal Wkly Rep 2002;902.
25. Storch GA, Radcliff JL, Meyer PL, Hinrichs JH. Methicillin-resistant Staphylococcus aureus in a nursing home. Infect Control 1987;8:24-29.
26. Budnick LD, Schaefler S. Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in New York health care facilities, 1988. The New York MRSA Study Group. Am J Public Health 1990;80:810-813.
27. Dennesen PJW, Bonten MJM, Weinstein RA. Multiresistant bacteria as a hospital epidemic problem. Ann Med 1998;30:176-185.
28. Moolenaar RL, Pasley-Shaw R, Harkess JR, et al. High prevalence of penicillin-nonsusceptible streptococcus pneumoniae at a community hospital in Oklahoma. Emerg Infect Dis 2000;6:283-289.
29. Niederman MS, Fein AM. Pneumonia in the elderly. Geriatr Clin North Am 1986;2:241-68.
30. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of muliply resistant pneumococci. N Engl J Med 1978;299:735-740.
31. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990;3:46-65.
32. Murray BE, Mederski-Samoraj B. Transferable B-lactamase: a new mechanism for in vitro penicillin resistance in streptococcus faecalis. J Clin Invest 1983;72:1168-1171.
33. Uttley AHC, Collins CH, Naidoo J, George RC. Vancomycin-resistant enterococci. Lancet 1988;I:57-58.
34. Leclercq R, Derlot E, Duval J, Courvalin P. Plasmid-mediated resistance to vancomycin and teicoplanin in enterococcus faecium. N Engl J Med 1988;319:157-161.
35. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997;24:545-556.
36. Witte W, Klare I. Glycopeptide-resistant enterococcus faecium outside hospitals: A commentary. Microb Drug Resist 1991;259-263.
37. Flournoy DJ. Antimicrobial susceptibilities of bacteria from nursing home residents in Oklahoma. Gerontology 1994;40:53-56.
38. Moellering RC Jr. Past, present and future antimicrobial agents. Am J Med 1995;99:11S-18S.
39. Plouffe JF. Emerging therapies for serious gram-positive bacterial infections: A focus on Linezolid. Clin Infect Dis 2000;31(Suppl 4):S144-S149.
40. Bonomo RA. Resistant pathogens in respiratory tract infections in older people. J Am Geriatr Soc 2002;50(7 Suppl):S236-S241.
41. Hooper DC. Mechanism of fluoroquinolone resistance. Drug Resist Update 1999;2:38-55.
42. Hooper DC. Mechanisms of action of antimicrobials: Focus on flouroquinolones. Clin Infect Dis 2001;32(Suppl 1):S9-S15.
43. Finch RG. Antibacterial activity of quinupristin/dalfopristin: Rationale for clinical use. Drugs 1996;51(Suppl 1):31-37.
44. Bonilla HF, Perri MG, Kauffman CA, Zervos MJ. Comparative in vitro activity of quinupristin/dalopristin against multidrug resistant enterococcus faecium. Diagn Microbiol Infect Dis 1996;25:127-131.
45. Moellering RC. A novel antimicrobial agent joins the battle against resistant bacteria. Ann Intern Med 1999;130:155-157.
46. Pai MP, Rodvold KA, Schreckenberger PC, et al. Risk factors associated with the development of infection with Linezolid- and Vancomycin-resistant enterococcus faecium. Clin Infect Dis 2002;35: 1269-1272.
47. Hererro IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant vancomycin-resistant enterococcus faecium. N Engl J Med 2002;346: 867-8.
48. Zyvox (package insert). Kalamazoo (MI): Pharmacia; 2000.
49. Batts DH. Linezolid clinical development program: end of phase II results [abstract]. Abstracts of 2nd European Congress of Chemotherapy; 10-13 May 1998; Hamburg, Germany.
50. Brickner SJ. Oxazolidinone antibacterial agents. Curr Pharm Des 1996; 2:175-194.
51. Attassi K, Hershberger E, Alam R, Zervos MJ. Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002;34:695-698.
52. Bemer-Melchior P, Juvin ME, Tassin S, et al. In vitro activity of the new ketolide telithromycin compared with those of macrolides against streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob Agents Chemother 2000;44:2999-3002.
53. Barry AL, Fuchs PC, Brown SD. In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and haemophilus influenzae. Antimicrob Agents Chemother 1998;42:2138-2140.